Cell-replacement therapy using Parkinson’s disease (PD) specific induced pluripotent stem cell
(iPSC) holds great promise in treating PD. However, the problem of iPSC safety and efficiency restrict its
clinical application. Meanwhile the requirement of skin biopsy for fibroblast will increase the risk of
complication. In the past few years, the advances of iPSC technology in efficiency, cell resource, safety and
cell culture have made it possible to use the derivatives of iPSCs to clinical PD treatment. This review will
summarize these progresses of iPSC technique in this fast-moving community.